Quarterly report pursuant to Section 13 or 15(d)

Segment Information - Schedule of Segment Information (Details)

v3.23.2
Segment Information - Schedule of Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jul. 01, 2023
Jul. 02, 2022
Jul. 01, 2023
Jul. 02, 2022
Segment Reporting Information [Line Items]        
Revenues $ 0 $ 0 $ 0 $ 0
Gross profit 0 0 0 0
Operating income (loss) (1,060) (658) (2,159) (1,339)
Depreciation and amortization     727 2
Interest (income) expense, net (365) (167) (840) (165)
Net income (loss) before income taxes 62 (227) (827) 2,392
Continuing Operations And Discontinuing Operations        
Segment Reporting Information [Line Items]        
Revenues 0 10,538 3,795 19,862
Gross profit 0 1,649 (197) 3,502
Operating income (loss) (1,060) 8,981 12,000 7,890
Depreciation and amortization 362 135 822 270
Interest (income) expense, net (365) 640 (659) 253
Net income (loss) before income taxes 63 8,878 13,149 10,092
Segment Reconciling Items [Member] | Discontinued Operations        
Segment Reporting Information [Line Items]        
Revenues 0 10,538 3,795 19,862
Gross profit 0 1,649 (197) 3,502
Operating income (loss) 0 9,639 14,159 9,229
Depreciation and amortization 0 135 96 268
Interest (income) expense, net 0 807 181 418
Net income (loss) before income taxes 1 9,105 13,976 7,700
Biotechnology | Operating Segments | Continuing Operations        
Segment Reporting Information [Line Items]        
Revenues 0 0 0 0
Gross profit 0 0 0 0
Operating income (loss) (1,060) (658) (2,159) (1,339)
Depreciation and amortization 362 0 726 2
Interest (income) expense, net (365) (167) (840) (165)
Net income (loss) before income taxes $ 62 $ (227) $ (827) $ 2,392